The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.
Philippa Corrie
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Andrea Marshall
No relevant relationships to disclose
Madusha Goonewardena
No relevant relationships to disclose
Janet A. Dunn
No relevant relationships to disclose
Mark R. Middleton
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - Roche
Paul D. Nathan
Research Funding - Roche
Other Remuneration - Roche
Martin Eric Gore
Consultant or Advisory Role - Roche
Honoraria - Roche
Neville Davidson
No relevant relationships to disclose
Steve Nicholson
Honoraria - Roche
Charles G. Kelly
No relevant relationships to disclose
Maria Marples
No relevant relationships to disclose
Sarah Danson
No relevant relationships to disclose
Ernest Marshall
No relevant relationships to disclose
Stephen Houston
No relevant relationships to disclose
Ruth E. Board
Honoraria - Roche
Other Remuneration - Roche
Ashita Marie Waterston
Research Funding - Roche
Other Remuneration - Roche
Jenny Nobes
Honoraria - Amgen; Roche
Mark Harries
Honoraria - Travel award & advisory board
Jim Barber
No relevant relationships to disclose
Paul Lorigan
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Expert Testimony - Roche (U)
Other Remuneration - Roche